Pascal Neuville has a PhD in molecular biology from University of Strasbourg, France. He spent five years at the University of Geneva as a post doc and then as Assistant Professor. Pascal then joined Transgene SA as an R&D project leader.
From 2002 to 2008, he was CSO of Faust Pharmaceuticals SA, a drug discovery and development company in CNS.
He founded Domain Therapeutics in 2008 as CEO. From 2008 to 2010, Pascal was President of Alsace BioValley’s Board of Directors, the life science competitiveness cluster of Alsace, and continued as a board member from 2010 to 2014.
He is also a member of the investment committee of SATT Conectus Alsace, the private TTO of the University of Strasbourg and regional research institutions and sits on the boards of Axilum Robotics and Defymed.